Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed performance with significant declines in the antigen business, disappointing gross margins, and uncertainty in Chinese sales resumption. Despite some positive developments in the QAPs business and cost control, the lack of profitability forecast for Q4 and unclear management responses in the Q&A section contribute to a negative outlook. The market cap suggests a moderate reaction, leading to a prediction of a -2% to -8% stock price movement.
Key Financial Performance
Revenue $4.2 million for Q1 fiscal 2026, up 13% from the prior quarter but down 30% year-over-year. The year-over-year decline was primarily due to a lack of sales through the distributor in China, which accounted for over $2 million in lost revenue. However, excluding the Chinese distributor, the antigen business grew by 5% quarter-over-quarter.
Net Loss $1.2 million for Q1 fiscal 2026. This was described as a controlled net loss, attributed to the company's ongoing efforts to recover sales and use of cash reserves.
Antigen Business Revenue Down 49% year-over-year due to the lack of sales through the Chinese distributor. Excluding this, the antigen business grew by 5% quarter-over-quarter.
QAPs Business Revenue $1.9 million for Q1 fiscal 2026, up 15% year-over-year. This growth reflects increased demand and new client programs.
Gross Margins Disappointing compared to last year and expectations. The decline was due to fewer products going through production, leading to lower absorption of fixed overheads. Margins are expected to improve as revenues approach the breakeven point of $5.5 million.
Operating Expenses At or below expected levels for Q1 fiscal 2026, reflecting cost control measures.
Cash Flow Cash consumption during Q1 was primarily due to timing of receivables. The company received $3.3 million in payments in January, increasing the cash balance to $10.6 million by the end of January.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New client programs: Microbix announced new client programs in molecular pathology and point-of-care genetics testing, expanding into oncology-related and genetics-related testing.
Recombinant antigens program: Launched the SARS-CoV-2 viral capsid antigen, strengthening supply chain, improving margins, and expanding product catalog.
Geographic expansion: New relationships with Sekisui in the U.S. for point-of-care testing and Seegene in Mexico for cervical cancer screening.
New client acquisition: College of American Pathologists became a client, enhancing credibility and revenue.
Operational efficiencies: Improved manufacturing throughput, yields, and reduced testing burden using electronic quality management systems.
Cost reduction: Incorporated recombinant capabilities to reduce production costs and secure supply chain.
Therapeutics program: Progress in Kinlytic program for blood clot resolution, with FDA feedback supporting updated production processes.
Revenue diversification: Reduced customer concentration issues by expanding client base and product offerings.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company experienced a significant 30% decline in revenues compared to the previous year, primarily due to a lack of sales through its distributor in China. This resulted in a $2 million shortfall in the antigen business, which was down 49%.
Gross Margin Pressure: Gross margins were disappointing due to lower sales volumes, which led to fewer products going through production and absorbing fixed overhead costs. The company needs to exceed $5.5 million in revenue to improve margins and profitability.
Customer Concentration Risk: The company faced setbacks with two large clients in the second half of fiscal 2025, highlighting the risks associated with customer concentration. Efforts are being made to diversify revenue streams.
Cash Flow Challenges: The company used $3 million in cash during the quarter, primarily due to timing issues with receivables. While cash reserves remain substantial, ongoing cash flow management is critical.
Supply Chain Disruptions: The company is working to strengthen its supply chain by adding recombinant capabilities to reduce costs and secure supply chains. However, this remains a work in progress.
Regulatory and Development Risks: The Kinlytic therapeutics program is progressing but involves regulatory complexities, including updates to production processes to meet contemporary standards. While feedback from the FDA has been constructive, the project carries inherent risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to recover sales above its engineered breakeven point of $5.5 million, which will improve margins and profitability. Sequential growth is anticipated as revenues increase.
Recombinant Antigens Program: The company has successfully onboarded recombinant antigen technologies, with the first commercial product being the SARS-CoV-2 viral capsid antigen. This is expected to strengthen the supply chain, improve margins, and expand the product catalog.
Operational Efficiencies: Efforts to reduce production costs, improve manufacturing throughput, and increase yields are ongoing. The company is leveraging electronic quality management systems and expects further cost reductions and efficiency improvements.
Therapeutics Program (Kinlytic): The Kinlytic program for resolving blood clots is progressing as planned. The company is addressing the $0.5 billion catheter clearance market and exploring larger opportunities in pulmonary embolism, deep vein thrombosis, and stroke. Feedback from the FDA has been constructive, and the project is advancing as expected.
QAPs Business Expansion: The company is expanding its QAPs business, including new relationships with the College of American Pathologists and other PT/EQA clients. This expansion is expected to enhance revenue and demonstrate thought leadership in the industry.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Was the sequential improvement at all due to seasonality?
A:No, there was no specific seasonality in the quarter. The improvement was attributed to order timing and product release by QC and QA, but not seasonality.
Q:Accounts receivable more than doubled versus Q4. Is there any unusual reason for that?
A:The increase was due to a resumption in client orders and timing of shipments. Receivables carried over quarter-end were higher, but they have since been collected, improving cash balances.
Q:OpEx in the quarter was low. Is that a seasonal effect, or should we see OpEx stable going forward?
A:Q1 tends to have lower OpEx due to reduced sales and marketing activities like trade shows. OpEx is expected to increase in Q2 and Q3 but remain consistent overall without dramatic jumps.
Q:When will China purchases start for the next flu season? Are you seeing any signs of sales resuming there?
A:China purchases are expected in late summer to early fall. Sales in China have not resumed significantly yet, as inventory from the previous season is still being consumed.
Q:What is the revenue potential with the College of American Pathologists?
A:The client is expected to generate six-figure revenue in 2026, with potential to grow into a meaningful seven-figure account as additional programs are rolled out.
Q:When would you typically see China start buying again for the next flu season if they’re going to?
A:Purchases are expected over late summer to early fall, depending on flu incidence and inventory levels.
Q:Was Sequel always aware that animal components would need to be replaced with synthetic?
A:Yes, this was known from the outset of the program. The replacement of animal components with synthetic ones is standard and expected.
Q:Would you expect any big QAPs customers to shift to commercial sales with any of your products this year?
A:The company is targeting large orders and programs with major multinationals, but these are aspirational and will be announced when finalized.
Q:Are any of the large orders expected for products that are commercial, not in development?
A:Yes, large orders can be for existing assays on existing platforms, new assays on existing platforms, or new assays on new platforms. Specific details depend on client programs.
Q:Do you still expect profitability to be reached by Q4?
A:Profitability in Q4 is unlikely but there should not be a significant loss. Annualized revenues are expected to be 30% above the Q3 low point, in the $18-$19 million range.
Q:What is the timing for final FDA approval?
A:The target for FDA approval remains late 2027. The process involves robust modernization of drug substance manufacturing and other steps before filing the sBLA.
Q:Has FDA confirmed the sBLA is okay given the replacement of animal products with synthetic?
A:The sBLA has not been filed yet. The replacement of animal components with synthetic ones is expected and uncontroversial, aligning with contemporary standards.
Q:Can China use the antigens they have in inventory, or do they need new antigens for new strains?
A:Antigens are designed to work across multiple strains and have a long shelf life if stored properly. Finished tests, however, have a defined shelf life and may expire if unused.
Q:Can you update us on the NCIB for the quarter and looking forward?
A:The company renewed its NCIB in December, allowing daily repurchases of up to 20,339 shares. Currently, 15,000 shares are being repurchased daily, with about 1 million shares repurchased to date.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on large orders and their potential impact, citing aspirational goals and the need to wait for finalized agreements. Additionally, they did not provide a clear timeline for profitability in Q4, emphasizing variability in order timing and revenue generation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
American Pathologists
CoV antigen
College American
EQA client
EQA program
FDA
Kinlytic
PT EQA
SARS CoV
antigen QAPs
assessment agency
breakeven point
cancer
capability
care
catheter
client program
consumption
contract manufacturer
drug
ingredient
lab
lack
meeting
pathology
product
production
receivables
relationship
revenue
supply chain
test
testing
update
GVA Transcript
Granite Construction Incorporated (GVA) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates positive financial performance with revenue, gross profit margin, net income, and operating cash flow all showing year-over-year improvements. The backlog increase suggests strong future revenue potential. Despite the lack of discussion on strategic initiatives, risks, and shareholder returns, the financial metrics and improved operational efficiencies provide a positive outlook. Given the market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
Unknown2-12
The earnings call reveals a mixed performance with significant declines in the antigen business, disappointing gross margins, and uncertainty in Chinese sales resumption. Despite some positive developments in the QAPs business and cost control, the lack of profitability forecast for Q4 and unclear management responses in the Q&A section contribute to a negative outlook. The market cap suggests a moderate reaction, leading to a prediction of a -2% to -8% stock price movement.
Granite Construction Incorporated (GVA) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call summary highlights a strong financial performance with increased cash gross profit and aggregate reserves. The Q&A session reveals positive sentiment from analysts, with management expressing confidence in growth, M&A strategy, and margin improvements. The company's strategic initiatives, such as federal opportunities and best value contracts, further support a positive outlook. The market cap suggests a moderate reaction, leading to a predicted stock price movement in the positive range (2% to 8%).
Granite Construction Incorporated (GVA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance with significant year-over-year improvements in revenue, gross profit, net income, and EBITDA, driven by acquisitions and operational efficiency. The Q&A section supports this positive outlook with expectations of continued growth and margin expansion, despite some uncertainties like weather impact. Revised guidance and successful acquisition integration further reinforce a positive sentiment. Given the company's market cap, the stock price is likely to experience a positive movement in the 2% to 8% range over the next two weeks.
GVA Slides
GVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
